The American Diabetes Association has testified before Congress about insulin price increases. Legislation targeting manufacturers (including 3 top insulin manufacturers) has been introduced to lower prescription medicine costs. At least 2 lawsuits have been filed in federal courts against insulin manufacturers for price gouging. Lastly, the FDA is stepping in to reclassify insulins from drugs to biologics (effective in March 2020). This will let biosimilar insulins enter the market, increasing competition and decreasing costs. In the meantime, help patients get manufacturer rebates and coupons to lower their insulin costs.
• Statement from FDA Commissioner Scott Gottlieb, M.D., on new actions advancing the agency’s biosimilars policy framework